Answers are grounded in this paper and cite their sources.
Introduction Despite the considerable progress made in cancer treatment through the development of target therapies, pancreatic ductal adenocarcinoma (PDAC) continues to exhibit resistance to this category of drugs. As a result, chemotherapy combination regimens remain the primary treatment approach for this aggressive cancer.
No takes yet. Share an insight, caveat, or question.
Deiana et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: